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Advanced age is an independent risk factor for cardiovascular diseases, which might be further exacerbated by estrogen deficiency.
Hormone replacement therapy (HRT) decreases cardiovascular risks and events in postmenopausal women; however, its effects are
not fully elucidated in older individuals. Thus, the aim of our study is to examine the impact of HRT on oxidant/antioxidant
homeostasis and cardiac remodeling. In our experiment, control (fertile) and aging (~20-month-old) female Wistar rats were
used. Aging rats were further divided into estrogen- (E2, 0.1mg/kg/day per os) or raloxifene- (RAL, 1.0mg/kg/day per os) treated
subgroups. After 2 weeks of treatment, cardiac heme oxygenase (HO) activity, total glutathione (GSH) content, matrix
metalloproteinase-2 (MMP-2) activity, and the concentrations of collagen type I and tissue inhibitor of metalloproteinase
(TIMP-2), as well as the infarct size, were determined. The aging process significantly decreased the antioxidant HO activity and
GSH content, altered the MMP-2/TIMP-2 signaling, and resulted in an excessive collagen accumulation, which culminated in
cardiovascular injury. However, 2 weeks of either E2 or RAL treatment enhanced the antioxidant defense mechanisms and
attenuated cardiac remodeling related to aging. Our findings clearly show that 2-week-long HRT is a potential intervention to
bias successful cardiovascular aging via reducing oxidative damage and cardiovascular dysfunction.
1. Introduction
Cardiac senescence is characterized by morphological and
functional changes that render the heart and vasculature to
be prone to cardiovascular diseases (CVDs). Although the
mechanisms underlying cardiovascular aging are complex
and involve multiple pathways, a growing body of evidence
shows that chronic oxidative stress is a key factor in the inci-
dence and progression of CVDs [1–3].
High levels of reactive oxygen species (ROS) may play a
critical role in the cellular damage during aging and lead to
an imbalance between the oxidant and antioxidant systems
[4]. Shift in the redox status can result from disturbances in
the antioxidant defense systems, including superoxide dis-
mutases, glutathione peroxidase, catalase, peroxiredoxin,
and nonenzymatic antioxidants, such as glutathione (GSH)
[5]. Age-related GSH depletion is associated with ROS over-
production and makes the heart more vulnerable to macro-
molecular damage affecting the physiological mechanisms
and function [6]. Additional ROS-sensitive defense mecha-
nisms involve the heme oxygenase (HO) enzyme system that
provides an adaptive cellular response against oxidative
injury and chronic inflammation by the conversion of heme
to the metabolites carbon monoxide (CO), free iron, and
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biliverdin [7]. Besides its antioxidant and anti-inflammatory
properties, increased activity of HO ameliorates left ventricu-
lar dysfunction, hypertrophy, and interstitial fibrosis and
improves tissue neovascularization with a great impact on
cardiac remodeling processes [8]. Due to the impaired
endogenous defense systems and increased production of
ROS, oxidative stress-induced pathways lead to maladaptive
fibrotic processes in the myocardium, thus promoting
the development of pathological cardiac remodeling. Age-
associated cardiomyocyte loss and excessive collagen deposi-
tion (i.e., fibrosis) result in the critical deterioration of the
extracellular matrix [9].
Numerous studies suggest that both oxidative and
fibrotic changes can be associated with the altered action of
estrogen via estrogen receptors. Estrogen binds to traditional
estrogen receptor alpha (ERα) and estrogen receptor beta
(ERβ), expressed in vascular endothelial cells, vascular
smooth muscle cells, and cardiomyocytes, thus playing an
important role in maintaining vascular tone, oxidant/antiox-
idant balance, and antifibrotic effects under healthy condi-
tions [10]. While estrogen exerts antioxidative, vasodilatory,
and antifibrotic effects, aging-mediated estrogen depletion
increases mitochondrial dysfunction and oxidative damage,
as well as inducing cardiac fibrosis via angiotensin II- and
endothelin 1-induced collagen accumulation [11].
Considerable evidence verifies a strong correlation among
biological age, sex, and cardiovascular risk. While the
incidence and progression of CVDs are less in premenopausal
women compared to age-matched men, as a consequence of
age-related estrogen deficiency, this sex advantage for women
decreases or disappears [12]. Although advanced age is an
independent risk factor for CVDs, reduced estrogen level
could further deteriorate cardiac outcomes in a female aging
population [13].
In this context, we hypothesize that replacement of
aging-induced estrogen loss may possess therapeutic efficacy
in the mitigation of cardiac oxidative damages. The main
purpose of our study is to examine the impact of hormone
replacement therapy on antioxidant defense systems and
cardiac remodeling in ovary-intact aged female rats.
2. Materials and Methods
2.1. Experimental Design. In our study, fertile control (n = 20)
and 20-month-old (aging) ovary-intact female Wistar rats
(n = 66) (Toxi-Coop Zrt., Hungary) were used and housed
(Directive 2010/63/EU) under constant temperature (20–
22°C) and humidity (40–50%) with a 12 h light/dark cycle.
Phytoestrogen-free chow and tap water were available ad libi-
tum. At the age of 20 months, aging rats were randomly
assigned (10-12 rats per group) to receive either estrogen
(E2, 0.1mg/kg/day oral treatment, Estrofem, Novo Nordisk
A/S, Bagsvaerd, Denmark) or raloxifene (RAL, 1.0mg/kg/day
oral treatment, Evista, Munich, Germany), which were calcu-
lated based on our previous study [14]. Each treatment was
carried out in our laboratory by the same person. Both E2
and RAL administration were always performed at the same
time of the day, preferably in the morning. The health status
of the animals was monitored before, during, and after the
treatments. In our experiment, all efforts were made to min-
imize the number of animals as well as the animal suffering.
After 2 weeks of treatment, both control and aging rats were
euthanized (100mg/kg thiopental, B. BraunMedical SA, Bar-
celona, Spain) and divided for induction of ischemia/reperfu-
sion (I/R) injury at a Langendorff perfusion apparatus or
were sacrificed for biochemical measurements. For biochem-
ical assays, heart samples were excised, nap frozen in liquid
nitrogen, and stored at –80°C for further biochemical
analysis. The experimental protocol and animal groups are
presented in Figure 1.
The animal protocols were examined and approved by
the Institutional Ethical Committee and were performed in
accordance with the standards of the European Community
guidelines on the care and use of laboratory animals (I.74-
40/2017. MÁB).
2.2. Measurement of Cardiac HO Activity. Cardiac samples
were homogenized in an ice-cold buffer (10.0mM N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid, 32.0mM
sucrose, 1.0mM dithiothreitol (DTT), 0.10mM ethylenedi-
aminetetraacetic acid disodium salt dihydrate (EDTA),
10.0μg/mL trypsin inhibitor, 10.0μg/mL leupeptin, and
2.0μg/mL aprotinin; pH7.4). After centrifugation at 15000
× g for 20min at 4°C, supernatant fractions were collected.
The reaction mix contained 2.0mM glucose-6-phosphate,
0.14U/mL glucose-6-phosphate dehydrogenase, 15.0μM
hemin, 120.0μg/mL rat liver cytosol as a source of biliverdin
reductase, 2.0mM MgCl2 × 6H2O, 100.0mM KH2PO4, and
150.0μL supernatant. The reaction was started by adding
100.0μL reduced β-nicotinamide adenine dinucleotide phos-
phate (β-NADPH) and incubation in the dark for 60min at
37°C. The reaction was stopped by ice cooling. The bilirubin
content was determined according to the optical density that
was measured at 465nm and 530nm, and the difference
between the two densities was calculated. HO activity was
defined as the amount of bilirubin (nmol) produced per hour
per mg protein [15].
2.3. Measurement of Cardiac Total Glutathione (GSH+GSSG)
Content. To determine the cardiac GSH+GSSG content,
heart samples were homogenized in a solution of 0.25M
sucrose, 1mM DTT, and 20mM Tris and then centrifuged
at 15000 × g for 30min at 4°C; then, 0.1M CaCl2, 0.25M
sucrose, 20mM Tris, and 1mM DTT were added to the
supernatants. After incubation at 0°C for 30min, the samples
were further centrifuged at 21450 × g for 60min at 4°C. As a
diluent buffer, a mixture of 125mM Na phosphate and
6.0mM EDTA was used for the stock solution of glutathione
(GSH), glutathione reductase, 5,5′dithio-bis-2-nitrobenzoic
acid (DTNB), and β-NADPH. A total volume of 40μL of
each blank, standard, or heart sample and equal volumes of
DTNB stock solution (20μL) and β-NADPH (140μL) were
added to each well and then incubated at 25°C for 5min. A
10μL volume of glutathione reductase was used to initiate
the reaction, and the absorbance was measured at 405 nm.
In the spectrophotometric assay for total GSH, GSH was
sequentially oxidized by DTNB and reduced by NADPH in
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the presence of glutathione reductase. Total glutathione
values were expressed as nmol/mg protein [16].
2.4. Measurement of Cardiac MMP-2 Activity. Gelatin zymo-
graphy was used to evaluate the MMP-2 activity in the car-
diac tissue. The protein concentration was determined by
the Bradford method, and then, 70μg protein was loaded to
the 8% sodium dodecyl sulfate- (SDS-) polyacrylamide gel
copolymerized with gelatin (20mg/mL; type A from porcine
skin; Sigma). Following electrophoresis, the gels were washed
with 2.5% Triton X-100 and incubated overnight at 37°C in
an incubation buffer containing 50mM Tris-HCl, 150mM
NaCl, and 5mM CaCl2. A staining method was performed
by using 0.05% Coomassie Brilliant Blue, and then, a mixture
of 4%methanol and 8% acetic acid was added to the gels. Fol-
lowing washing procedures, the gels were digitally scanned
and analyzed by using Quantity One software. MMP-2
human recombinant (Sigma-Aldrich, Hungary) was used as
a positive control to identify MMP-2 activities, which were
expressed as intensity × mm2 [16].
2.5. Measurement of Collagen Type I and TIMP-2
Concentrations. Cardiac samples were homogenized in phos-
phate buffer (pH7.4) for 20 seconds. After centrifugation
(20min, 2500 rpm, 4°C), supernatants were collected carefully
and used for ELISA (GenAsia, Shanghai) and protein mea-
surements. During ELISA measurements, blank, standard,
and LV supernatants were probed by using a second antibody
labeled with biotin for 60 minutes at 37°C. After washing pro-
cedures, samples were incubated with chromogen A and B
solutions for 10 minutes at 37°C, and then, the reaction was
stopped. Both collagen type I and TIMP-2 concentrations
were determined at 450nm and given as ng/mg protein.
2.6. Protein Determination. Using a commercial protein
assay kit (Bio-Rad Labs), 20μL aliquots of the samples was
mixed with 980μL of distilled water, and then, 200μL Brad-
ford reagent was added to each dilution. After mixing and
following 10min incubation, the standard and sample dilu-
tions were assayed spectrophotometrically at 595 nm. Protein
levels were expressed as mg protein/mL.
2.7. Regional Ischemia/Reperfusion Protocol. Rat hearts were
isolated, transferred to the Langendorff perfusion apparatus,
and perfused with Krebs-Henseleit buffer (11.2mM glucose,
1.24mM KH2PO4, 20.1mM NaHCO3, 119mM NaCl,
4.7mM KCl, 1.25mM CaCl2, and 1.24mM MgSO4) equili-
brated with 95% O2 and 5% CO2 at 37
°C. After 10min of
stabilization, regional ischemia was induced by ligation of
the left anterior descending (LAD) coronary artery for
30min, and then, reperfusion was maintained for 120min.
At the end of the reperfusion, hearts were stained with 1%
Evans blue solution via the cannula. Heart samples were
frozen at –20°C overnight [16].
2.8. Evaluation of Infarct Size. Frozen hearts were cut into
2mm thick cross-sectional slices, which were stained with
1% 2,3,5-triphenyltetrazolium chloride (TTC) solution pre-
pared in phosphate buffer saline (pH7.4) and incubated for
10min at 37°C. After TTC staining, the slices were trans-
ferred to a formalin solution for 10min and then placed to
phosphate buffer (pH7.4). Heart slices were then placed
between two sheets of glass and scanned into a computer,
and infarct size was calculated as the percentage of the area
at risk.
2.9. Statistical Analysis. The results are expressed as means
± S:E:M. After verifying the Gaussian distribution of data
in the groups by means of the Shapiro-Wilk test, differences
of means among the groups were compared using one-way
ANOVA followed by the Tukey posttest, and p < 0:05 was
considered to be significant.
Aging ♀
Aging ♀ + E2
Aging ♀ + RAL
Randomization
- HO activity
- GSH content
- Collagen type-1
concentration
- MMP-2 activity
- TIMP-2 concentration
Biochemical
measurements 
Animals
Female
Wistar rats
Sacrificing
Estrogen (E2)
(0.1 mg/kg/day) treatment
or
Raloxifene (RAL)
(1.0 mg/kg/day) treatment 
2 weeks
Aging process
At the age of 20 months
Ischemia-
reperfusion
protocol
-Infarct size
Figure 1: The experimental protocol of the study. E2: estrogen; RAL: raloxifene; HO: heme oxygenase; GSH: glutathione; MMP-2: matrix
metalloproteinase-2; TIMP-2: tissue inhibitor of matrix metalloproteinase-2.
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3. Results
3.1. Measurement of Cardiac HO Activity. In our experiment,
HO activity was defined as the amount of bilirubin (nmol)
produced per hour per mg protein. Regarding the shift in
redox status, the antioxidant HO enzyme activity signifi-
cantly decreased in the myocardium of aged rats compared
to the control animals. Two weeks of either E2 or RAL treat-
ment enhanced the HO activity, thus indicating improve-
ment in redox balance. Data and p values are presented in
Figure 2.
3.2. Measurement of Cardiac Total Glutathione (GSH+GSSG)
Content. GSH is a critical nonenzymatic antioxidant that
protects the heart against oxidative damage. Our findings
show that advanced age is associated with GSH depletion;
nevertheless, a decreased GSH value was restored by hor-
mone replacement therapy. While oral administration of E2
resulted in a ~40% increase compared to the aging group,
RAL treatment elevated (~100%) the GSH content more
efficiently. Data and p values are presented in Figure 3.
3.3. Measurement of Cardiac Collagen Type I Concentration.
To determine the age-induced alterations in fibrotic mecha-
nisms and to test the potential protective effects of hormone
replacement therapies, cardiac collagen type I concentration
was measured. Our data revealed significant remodeling in
the hearts of aged rats. Aging animals displayed 9-fold higher
collagen accumulation compared to the control counterparts;
however, 2-week-long administration of E2 and RAL signifi-
cantly reduced the pathological collagen content. Data and
p values are presented in Figure 4.
3.4. Measurement of Cardiac MMP-2 Activity. If hormone
replacement therapy exhibits protective effects on the aged
hearts by modulating collagen degradation, then an effect
on MMP-2 activation was expected. Our results show that
the aging process resulted in a 70% decrease in the MMP-2
activity compared to the control group. In addition, both
E2 and RAL treatments significantly increased the cardiac
MMP-2 activity. Data and p values are presented in
Figure 5(a).
3.5. Measurement of Cardiac TIMP-2 Concentration. To
examine whether hormone replacement therapy modulates
and upregulates MMP-2 activity, its tissue inhibitor was also
tested. Similar to the MMP-2 activity, we found that cardiac
TIMP-2 concentration was significantly reduced in the aged
hearts. Data and p values are presented in Figure 5(b).
3.6. Evaluation of Infarct Size. As shown in Figure 6, a signif-
icant increase in the ratio of infarct size was observed in the
aged hearts compared to the control group. Again, adminis-
tration of E2 or RAL replacement resulted in a significant
decrease compared to the aging counterparts, suggesting
the protective effects of hormone replacement therapy on
myocardial I/R injury. The mean values of the area at risk
(AAR) are as follows: control: 41.99, aging: 43.56, aging+E2:
39.48, and aging+RAL: 42.95.
4. Discussion
With a keen awareness that aging is an independent risk
factor for CVDs, a better understanding of the potential bio-
logical mechanisms underlying cardiovascular aging and
pursuits to decrease the risk of CVDs are necessary to
improve the quality of life for the elderly. Epidemiological
data verify the sex advantage of premenopausal women
against CVDs; however, this favorable property becomes far
less or disappears with advanced age due to reduced estrogen
level [12, 17]. Under physiological conditions, estrogen
possesses antioxidant effects, attenuates inflammation, and
induces angiogenesis as well as vasorelaxation that protect
the heart against molecular and functional injuries [10]. Nev-
ertheless, the estrogen-mediated cardioprotective effects are
reduced during aging due to the fluctuation of 17β-estradiol
level, which is the most potent estrogen during the premeno-
pausal period. The reduction of estrogen synthesis, changes
in estrogen receptors, and alterations of signaling pathways
related to the aging process increase the risk of complex
cardiovascular damages [18].
The use of hormone replacement therapy (HRT) is still
controversial. The reason for the different characterization
of HRT includes many factors that contribute to the various
outcomes, among them the duration and dosage of the hor-
mone administration [19, 20]. While most research studies
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focus on the ovariectomy-induced estrogen depletion, less
information is available on the age-related response to hor-
mone replacement therapy. Therefore, our experimental pro-
tocol was designed to evaluate the hypothesis that HRT may be
a potential therapeutic strategy to achieve successful aging via
reducing cardiac risk factors. Our findings show that age-
induced decrease in estrogen level (control: 287:91 ± 6:73 ng/L,
aging: 171:77 ± 7:00 ng/L) reflected on the measured ex vivo
and biochemical parameters via altering the redox status and
inducing abnormal cardiac remodeling; however, 2 weeks of
HRT (estrogen or raloxifene) was able to restore the adverse
effects.
As it is well known, oxidative damage occurs as a result of
the failure in antioxidant mechanisms to eliminate ROS pro-
duction. Numerous studies verify that HO is a key molecule
against oxidative injuries through its antioxidant and anti-
inflammatory properties [21–23]. The HO isoforms (HO-1,
HO-2, and HO-3) are known to catalyse the oxidation of
heme to generate free iron, CO, and biliverdin, which is sub-
sequently reduced to bilirubin by biliverdin reductase. Both
biliverdin and bilirubin possess antioxidant capacity, while
CO is a vasodilator and anti-inflammatory and antiapoptotic
molecule [24, 25]. In our study, we detected that the aging
process significantly reduced the HO enzyme activity com-
pared to the control/fertile group, which suggests that cells
became more vulnerable to oxidative insult. In a previous
study, Ungvari et al. investigated the role of a nuclear factor
erythroid-2 related factor-2 (Nrf2) redox-sensitive transcrip-
tional regulator in cardiovascular aging [26]. During physio-
logical conditions, Nrf2 leads to the upregulation of various
antioxidant genes, such as HO-1; however, age-related ROS
production fails to activate Nrf2, resulting in oxidative
damage and inflammation. In another study, Kwon et al.
evaluated the effect of the Nrf2/HO-1 signaling pathway
on antioxidant capacity [27]. Their results showed that
Nrf2/HO-1 signaling resulted in an enhancement of GSH
content, whereas inhibition of the HO-1 activity eliminated
the cytoprotective effect of GSH. In our work, the aging pro-
cess caused a similar reduction in both HO activity and GSH
content, which suggests that these antioxidant mechanisms
may be mediated through Nrf2 signaling. While aging/estro-
gen deficiency was associated with shift in the redox status,
estrogen and raloxifene treatments exert protective effects
on the cardiac antioxidant status via increasing HO activity
and GSH level. These results are in accordance with our
earlier observations, where the antioxidative role of estrogen
and raloxifene was verified in ovariectomized rat models
[14]. Raloxifene is a selective estrogen receptor modulator
(SERM), which acts either as an estrogen agonist or as an
antagonist in a tissue-selective manner. This benzothiophen
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derivate binds with high affinity to the nuclear estrogen
receptor; thus, its pharmacological profile is similar to that
of estrogen, particularly in the cardiac tissue [28]. Konyalio-
glu et al. reported that 1mg/kg raloxifene treatment caused a
significant elevation in the cardiac GSH level of ovariecto-
mized rats [29]. Reduction of GSH due to ovariectomy-
induced estrogen loss or the aging process is due to a yield
of ROS overproduction, which promotes oxidative damage
and inflammatory processes.
Considerable evidence has been published that cardiac
senescence is associated with mitochondrial dysfunction,
mitochondrial DNA mutations, and oxidative damage to
respiratory enzymes, which result in a significant increase
in ROS [30]. In agreement with the beneficial role of estrogen
on the heart, estrogen receptors localized on the mitochon-
drial membrane are significant elements of estrogen-
mediated cell survival and cardioprotection. Previous studies
proved that activation of mitochondrial ERα, ERβ, and
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GPR30 receptors protects against ex vivo I/R injury, results
in a smaller infarct size, and possesses an ROS scavenging
role [31].
Given the complexity of age-mediated ROS accumulation
and disruption of antioxidant defense mechanisms, the heart
is especially prone to oxidative damage and morphological
and functional alterations. Therefore, aging is considered a
predisposing factor for cardiac fibrosis, which is character-
ized by decreased myocyte number, increased myocyte size,
and accumulation of the extracellular matrix (ECM), espe-
cially the collagen [32]. Myocardial ECM is essential for
proper cardiac structural integrity and pump function and
possesses a mediator role in the modulation of the cardiac
phenotype during hypertrophy [33]. ECM depends on a
well-controlled balance between the matrix metalloprotein-
ases (MMPs) and the tissue inhibitor of metalloproteinases
(TIMPs). MMPs are Ca2+ and Zn2+-dependent proteases that
are synthesized as inactive forms or pro-MMP and can be
activated by removal of an amino-terminal propeptide
domain. Among the 26MMPs, MMP-2 is involved in cardiac
remodeling via cleaving collagen type I and type III.
Although activated MMPs intensively degrade the ECM pro-
teins, their endogenous inhibitors, namely, TIMPs, have a
compensatory role to prevent excessive ECM degradation
[34]. Therefore, the balance between MMPs and TIMPs
determines the synthesis and degradation of cardiac ECM.
During aging, the ECM remodeling is disrupted, which
induces excessive collagen accumulation in the heart (i.e.,
fibrosis) [35]. Our data prove that the aging process increases
the cardiac collagen content via disrupting the MMP-
2/TIMP balance. We found that collagen type I concentra-
tion significantly increased in aged hearts compared to the
control/fertile counterparts. Consistent with Kwak et al., we
noted that age-associated collagen deposition is a conse-
quence of cellular events including increased collagen syn-
thesis and decreased degradation, which resulted from the
disruption of MMP-2/TIMP signaling [36]. Our hypothesis
whether hormone replacement therapy plays a beneficial role
in the cardiac remodeling was underpinned with the reduced
collagen level and the elevated MMP-2/TIMP values. Similar
to our findings, Mountain et al. demonstrated a significant
reduction in MMP-2 and TIMP-2 levels in response to ovari-
ectomy; however, hormone replacement therapy resulted in
the upregulation of MMP-2, indicating that hormone substi-
tution modulated the MMP-2 regulatory pathway [37]. In
another research work, Xu et al. supported the antifibrotic
effects of estrogen in the prevention of left ventricular remod-
eling [38]. Estrogen replacement therapy was indicated to
reduce left ventricular weight and collagen accumulation in
12-month-old ovariectomized rats, via enhancing MMP-2
activity. Furthermore, they verified that aging-mediated
collagen accumulation and the decreased MMP-2 activity
were associated with the downregulation of ERα and ERβ.
Besides antioxidative and anti-inflammatory properties,
numerous studies indicate in different models that HO
possesses a favorable impact on cardiac remodeling. Wang
et al. established that the upregulation of HO-1 promoted
neovascularization and limited oxidative stress, myofiber
hypertrophy, and interstitial fibrosis, which were associated
with improved chamber remodeling and systolic/diastolic
function [8]. Further finding supported the beneficial role
of HO in the attenuation of cellular senescence during the
development of myocardial infarction in an aged heart [39].
In view of the importance that HO serves as a defense
mechanism against oxidative stress and in cardiac remodel-
ing, we investigated its potential role in I/R injury in aged
rats. Accumulating data showed that the HO/CO pathway
is a potential defense line against I/R injury [39, 40]. Upon
the release of CO, it activates the enzyme soluble guanylate
cyclase (sGC) and induces vasorelaxation by increasing cyclic
guanosine monophosphate (cGMP). Studies with ovariecto-
mized rats supported that excessive generation of ROS pro-
moted oxidative damage and inflammation and impaired
the sensitivity for cardiac ischemia, although hormone
replacement seemed to be an effective therapy in the mitiga-
tion of adverse effects [13, 14]. Similar to these observations,
our results clearly show that both estrogen and raloxifene
substitution significantly decreased the ischemic ratio after
LAD occlusion, which may be consequently associated with
the upregulation of the HO system in aged rats.
In our present study, we gained insights into age-related
disturbances in oxidant/antioxidant homeostasis and adverse
fibrotic mechanisms. A better understanding of the molecu-
lar and cellular mechanisms underlying cardiovascular aging
provides potential targets for specific interventions to delay
or prevent pathological cardiac processes. Our findings show
that both estrogen and raloxifene replacements restored anti-
oxidant defense systems and reduced the excessive collagen
accumulation via enhancing the MMP-2/TIMP-2 signaling
mechanism. The increase in HO activity and GSH content
as well as the improvement in fibrotic processes could reduce
I/R-induced necrotic ratio. In this sense, we can conclude
that 2-week-long low-dose estrogen or raloxifene replace-
ment therapy seems to be an efficient approach to promote
successful cardiovascular aging.
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